aflibercept

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Polypoidal Choroidal Vasculopathy Without Active Polyp

Conditions

Polypoidal Choroidal Vasculopathy Without Active Polyp

Trial Timeline

Feb 1, 2014 → Nov 2, 2017

NCT ID

NCT02072408

About aflibercept

aflibercept is a approved stage product being developed by Bayer for Polypoidal Choroidal Vasculopathy Without Active Polyp. The current trial status is completed. This product is registered under clinical trial identifier NCT02072408. Target conditions include Polypoidal Choroidal Vasculopathy Without Active Polyp.

What happened to similar drugs?

4 of 6 similar drugs in Polypoidal Choroidal Vasculopathy Without Active Polyp were approved

Approved (4) Terminated (0) Active (2)

✅Verteporfin Photodynamic Therapy + RanibizumabNovartisApproved

✅Intravitreal aflibercept injection 2.0mgRegeneron PharmaceuticalsApproved

✅Rescue Intravitreal Aflibercept InjectionRegeneron PharmaceuticalsApproved

✅Aflibercept Intravitreous InjectionBayerApproved

🔄Brolucizumab 6mg + Brolucizumab 6mgNovartisPhase 3

🔄aflibercept 8 mgBayerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04113538	Phase 3	UNKNOWN	Jul 24, 2019	May 1, 2023	Wet Age-related Macular Degeneration
NCT02633852	Approved	Completed	May 24, 2016	Sep 6, 2018	Diabetic Macular Edema (DME)
NCT02661711	Phase 2	Completed	Mar 1, 2016	Oct 1, 2017	Macular Oedema
NCT02072408	Approved	Completed	Feb 1, 2014	Nov 2, 2017	Polypoidal Choroidal Vasculopathy Without Active Polyp
NCT02157077	Phase 3	Completed	Dec 1, 2013	Dec 1, 2015	Macular Degeneration
NCT01950741	Approved	Completed	Sep 1, 2013	Aug 1, 2015	Exudative Age-related Macular Degeneration

Competing Products

9 competing products in Polypoidal Choroidal Vasculopathy Without Active Polyp

See all competitors

Product	Company	Stage	Hype Score
Zimura + Eylea	Astellas Pharma	Phase 2	27
Avacincaptad Pegol	Astellas Pharma	Phase 2	35
Verteporfin Photodynamic Therapy + Ranibizumab	Novartis	Approved	43
Brolucizumab 6mg + Brolucizumab 6mg	Novartis	Phase 3	40
Intravitreal aflibercept injection 2.0mg	Regeneron Pharmaceuticals	Approved	43
Rescue Intravitreal Aflibercept Injection	Regeneron Pharmaceuticals	Approved	39
Aflibercept Intravitreous Injection	Bayer	Approved	47
aflibercept 8 mg	Bayer	Phase 3	44
ranibizumab intravitreal injection	Pacific Biosciences	Phase 1	19